

Relief From Irritable Bowel Syndrome

References

1. Kennedy PJ, Cryan JF, Dinan TG, Clarke G. Irritable bowel syndrome: a microbiome-gut-brain axis disorder? *World J Gastroenterol*. 2014 Oct 21;20(39):14105-25.
2. Coss-Adame E, Rao SS. Brain and gut interactions in irritable bowel syndrome: new paradigms and new understandings. *Curr Gastroenterol Rep*. 2014 Apr;16(4):379.
3. Fichna J, Storr MA. Brain-gut interactions in IBS. *Front Pharmacol*. 2012 Jul 5;3:127.
4. Crouzet L, Gaultier E, Del'Homme C, et al. The hypersensitivity to colonic distension of IBS patients can be transferred to rats through their fecal microbiota. *Neurogastroenterol Motil*. 2013 Apr;25(4):e272-82.
5. Moloney RD, O'Leary OF, Felice D, Bettler B, Dinan TG, Cryan JF. Early-life stress induces visceral hypersensitivity in mice. *Neurosci Lett*. 2012 Mar 23;512(2):99-102.
6. Balestra B, Vicini R, Cremon C, et al. Colonic mucosal mediators from patients with irritable bowel syndrome excite enteric cholinergic motor neurons. *Neurogastroenterol Motil*. 2012 Dec;24(12):1118-e570.
7. Available at: <http://womenshealth.gov/publications/our-publications/fact-sheet/irritable-bowel-syndrome.html>. Accessed April 10, 2015.
8. Magge S, Lembo A. Low-FODMAP Diet for Treatment of Irritable Bowel Syndrome. *Gastroenterol Hepatol (N Y)*. 2012 Nov;8(11):739-45.
9. Lacy BE, Weiser K, De Lee R. The treatment of irritable bowel syndrome. *Therap Adv Gastroenterol*. 2009 Jul;2(4):221-38.
10. Basseri RJ, Kunkel D, Low K, Conklin JL, Pimentel M. Importance of diarrhea in evaluating constipation in irritable bowel syndrome clinical studies. *J Clin Gastroenterol*. 2011 Oct;45(9):790-3.
11. Farthing MJ. Treatment options in irritable bowel syndrome. *Best Pract Res Clin Gastroenterol*. 2004 Aug;18(4):773-86.
12. Scarpignato C, Pelosini I. Management of irritable bowel syndrome: novel approaches to the pharmacology of gut motility. *Can J Gastroenterol*. 1999 Mar;13 Suppl A:50A-65A.
13. Buchwald-Werner S, Fujii H, Reule C, Schoen C. Perilla extract improves gastrointestinal discomfort in a randomized placebo controlled double blind human pilot study. *BMC Complement Altern Med*. 2014;14:173.
14. Coelho VR, Vieira CG, de Souza LP, et al. Antiepileptogenic, antioxidant and genotoxic evaluation of rosmarinic acid and its metabolite caffeic acid in mice. *Life Sci*. 2015 Feb 1;122:65-71.
15. Etienne-Mesmin L, Livrelli V, Privat M, et al. Effect of a new probiotic *Saccharomyces cerevisiae* strain on survival of *Escherichia coli* O157:H7 in a dynamic gastrointestinal model. *Appl Environ Microbiol*. 2011 Feb;77(3):1127-31.
16. Sivignon A, Vandekerckove P, Barnich N, Pignède G, Darfeuille-Michaud A. *Saccharomyces cerevisiae* as a therapeutic tool to prevent colonization of the gut by adherent-invasive *E. coli* in Crohn's disease patients. *Gastroenterology*. 2010 May;138(5):S-51.
17. Lacy BE, Weiser K, De Lee R. The treatment of irritable bowel syndrome. *Therap Adv Gastroenterol*. 2009 Jul;2(4):221-38.
18. Talley NJ. Dietary modification as a treatment for irritable bowel syndrome. *Gastroenterol Hepatol (N Y)*. 2012 Aug;8(8):552-4.
19. Neal KR, Barker L, Spiller RC. Prognosis in post-infective irritable bowel syndrome: a six-year follow up study. *Gut*. 2002 Sep;51(3):410-3.
20. Isolauri E, Rautava S, Kalliomäki M. Food allergy in irritable bowel syndrome: new facts and old fallacies. *Gut*. 2004 Oct;53(10):1391-3.
21. Leeds JS, Hopper AD, Sidhu R, et al. Some patients with irritable bowel syndrome may have exocrine pancreatic insufficiency. *Clin Gastroenterol Hepatol*. 2010 May;8(5):433-8.
22. Stark D, van Hal S, Marriott D, Ellis J, Harkness J. Irritable bowel syndrome: a review on the role of intestinal protozoa and the importance of their detection and diagnosis. *Int J Parasitol*. 2007 Jan;37(1):11-20.
23. Nagel R, Bielefeldt-Ohmann H, Traub R. Clinical pilot study: efficacy of triple antibiotic therapy in Blastocystis positive irritable bowel syndrome patients. *Gut Pathog*. 2014 Aug 20;6:34.
24. Goepf JG, McBride T, Fowler E, Peace-Brewer A, Landis D. Fecal biomarker testing identifies exocrine pancreatic insufficiency in patients with possible irritable bowel syndrome. *AACC 2014 Annual Meeting and Clinical Lab Expo*. 2014.
25. Goepf J, Fowler E, McBride T, Landis D. Frequency of abnormal fecal biomarkers in irritable bowel syndrome. *Glob Adv Health Med*. 2014 May;3(3):9-15.
26. Bouchoucha M, Devroede G, Raynaud JJ, Bon C, Bejou B, Benamouzig R. Is the colonic response to food different in IBS in contrast to simple constipation or diarrhea without abdominal pain? *Dig Dis Sci*. 2011 Oct;56(10):2947-56.

27. Lee YJ, Park KS. Irritable bowel syndrome: emerging paradigm in pathophysiology. *World J Gastroenterol*. 2014 Mar 14;20(10):2456-69.
28. Zhou Q, Verne GN. New insights into visceral hypersensitivity-clinical implications in IBS. *Nat Rev Gastroenterol Hepatol*. 2011 Jun;8(6):349-55.
29. Kanazawa M, Hongo M, Fukudo S. Visceral hypersensitivity in irritable bowel syndrome. *J Gastroenterol Hepatol*. 2011 Apr;26 Suppl 3:119-21.
30. Dong WZ, Zou DW, Li ZS, et al. Study of visceral hypersensitivity in irritable bowel syndrome. *Chin J Dig Dis*. 2004;5(3):103-9.
31. Barbara G, Cremon C, Annese V, et al. Randomised controlled trial of mesalazine in IBS. *Gut*. 2014 Dec 22.
32. Matricon J, Meleine M, Gelot A, et al. Associations between immune activation, intestinal permeability and the irritable bowel syndrome. *Aliment Pharmacol Ther*. 2012 Dec;36(11-12):1009-31.
33. Bercik P, Verdu EF, Collins SM. Is irritable bowel syndrome a low-grade inflammatory bowel disease? *Gastroenterol Clin North Am*. 2005 Jun;34(2):235-45.
34. Turcotte JF, Kao D, Mah SJ, et al. Breaks in the wall: increased gaps in the intestinal epithelium of irritable bowel syndrome patients identified by confocal laser endomicroscopy (with videos). *Gastrointest Endosc*. 2013 Jan 25.
35. Locke GR 3rd, Zinsmeister AR, Talley NJ, Fett SL, Melton LJ. Risk factors for irritable bowel syndrome: role of analgesics and food sensitivities. *Am J Gastroenterol*. 2000 Jan;95(1):157-65.
36. Sundin J, Rangel I, Fuentes S, et al. Altered faecal and mucosal microbial composition in post-infectious irritable bowel syndrome patients correlates with mucosal lymphocyte phenotypes and psychological distress. *Aliment Pharmacol Ther*. 2015 Feb;41(4):342-51.
37. Tojo R, Suarez A, Clemente MG, et al. Intestinal microbiota in health and disease: role of bifidobacteria in gut homeostasis. *World J Gastroenterol*. 2014 Nov 7;20(41):15163-76.
38. Jalanka-Tuovinen J, Salojarvi J, Salonen A, et al. Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. *Gut*. 2014 Nov;63(11):1737-45.
39. Collins SM, Denou E, Verdu EF, Bercik P. The putative role of the intestinal microbiota in the irritable bowel syndrome. *Dig Liver Dis*. 2009 Dec;41(12):850-3.
40. La JH, Kim TW, Sung TS, Kang JW, Kim HJ, Yang IS. Visceral hypersensitivity and altered colonic motility after subsidence of inflammation in a rat model of colitis. *World J Gastroenterol*. 2003 Dec;9(12):2791-5.
41. Hong SN, Rhee PL. Unraveling the ties between irritable bowel syndrome and intestinal microbiota. *World J Gastroenterol*. 2014 Mar 14;20(10):2470-81.
42. Barbara G, Stanghellini V, Cremon C, et al. Aminosalicylates and other anti-inflammatory compounds for irritable bowel syndrome. *Dig Dis*. 2009;27 Suppl 1:115-21.
43. Sainsbury A, Ford AC. Treatment of irritable bowel syndrome: beyond fiber and antispasmodic agents. *Therap Adv Gastroenterol*. 2011 Mar;4(2):115-27.
44. Chey WD, Eswaran S, Kurlander J. JAMA patient page. Irritable bowel syndrome. *JAMA*. 2015 Mar 3;313(9):982.
45. Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. *Gastroenterology*. 2014 Jan;146(1):67-75.e5.
46. Ladabaum U, Boyd E, Zhao WK, et al. Diagnosis, comorbidities, and management of irritable bowel syndrome in patients in a large health maintenance organization. *Clin Gastroenterol Hepatol*. 2012 Jan;10(1):37-45.
47. Wang Z, Fan J, Liu M, et al. Nutraceuticals for prostate cancer chemoprevention: from molecular mechanisms to clinical application. *Expert Opin Investig Drugs*. 2013 Dec;22(12):1613-26.
48. Ferrari CK. Functional foods, herbs and nutraceuticals: towards biochemical mechanisms of healthy aging. *Biogerontology*. 2004;5(5):275-89.
49. Bachheti RK, Joshi A, Ahmed T. A phytopharmacological overview of perilla frutescens. *Int J Pharm Sci Rev Res*. May- Jun 2014; 26(2):55-61.
50. Legras JL, Merdinoglu D, Cornuet JM, Karst F. Bread, beer and wine: *Saccharomyces cerevisiae* diversity reflects human history. *Mol Ecol*. 2007 May;16(10):2091-102.
51. Available at: <http://www.itmonline.org/articles/perilla/perilla.htm>. Accessed April 21, 2015.
52. Verspohl EJ, Fujii H, Homma K, Buchwald-Werner S. Testing of Perilla frutescens extract and Vicenin 2 for their antispasmodic effect. *Phytomedicine*. 2013 Mar 15;20(5):427-31.
53. Atack JR. The benzodiazepine binding site of GABA(A) receptors as a target for the development of novel anxiolytics. *Expert Opin Investig Drugs*. 2005 May;14(5):601-18.
54. Albertin W, Marullo P, Aigle M, Dillmann C, de Vienne D, Bely M, Sicard D. Population size drives industrial *Saccharomyces cerevisiae* alcoholic fermentation and is under genetic control. *Appl Environ Microbiol*. 2011 Apr;77(8):2772-84.
55. Brandt LJ, Chey WD, Foxx-Orenstein AE, et al. An evidence-based position statement on the management of irritable bowel syndrome. *Am J Gastroenterol*. 2009 Jan;104 Suppl 1:S1-35.
56. El-Salhy M, Gilja OH, Hatlebakk JG, Hausken T. Stomach antral endocrine cells in patients with irritable bowel syndrome. *Int J Mol Med*. 2014 Oct;34(4):967-74.

57. El-Salhy M, Gilja OH, Gundersen D, Hatlebakk JG, Hausken T. Endocrine cells in the ileum of patients with irritable bowel syndrome. *World J Gastroenterol*. 2014 Mar 7;20(9):2383-91.
58. El-Salhy M, Gundersen D, Hatlebakk JG, Gilja OH, Hausken T. Abnormal rectal endocrine cells in patients with irritable bowel syndrome. *Regul Pept*. 2014 Jan 10;188:60-5.
59. Agah S, Taleb AM, Moeini R, Gorji N, Nikbakht H. Cumin extract for symptom control in patients with irritable bowel syndrome: a case series. *Middle East J Dig Dis*. 2013 Oct;5(4):217-22.
60. Camilleri M, Lasch K, Zhou W. Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. *Am J Physiol Gastrointest Liver Physiol*. 2012 Oct;303(7):G775-85.
61. Apkarian AV, Bushnell MC, Treede RD, Zubieta JK. Human brain mechanisms of pain perception and regulation in health and disease. *Eur J Pain*. 2005 Aug;9(4):463-84. Epub 2005 Jan 21. Review.
62. Buchwald-Werner S, Fujii H. Prokinetic and antispasmodic constituent discovered in *Perilla frutescens* – Development of a gut health ingredient. *Planta Med*. 2012; 78 - CL61.
63. Available at: <http://www.mayoclinic.org/diseases-conditions/crohns-disease/basics/symptoms/con-20032061>. Accessed April 17, 2015.
64. Yang GY, Taboada S, Liao J. Inflammatory bowel disease: a model of chronic inflammation-induced cancer. *Methods Mol Biol*. 2009;511:193-233.
65. Rubin DC, Shaker A, Levin MS. Chronic intestinal inflammation: inflammatory bowel disease and colitis-associated colon cancer. *Front Immunol*. 2012 May 8;3:107.
66. Available at: <http://www.mayoclinic.org/diseases-conditions/ulcerative-colitis/basics/symptoms/con-20043763>. Accessed April 17, 2015.
67. Veloso FT, Carvalho J, Magro F. Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. *J Clin Gastroenterol*. 1996 Jul;23(1):29-34.
68. Fiocchi C. The immune system in inflammatory bowel disease. *Acta Gastroenterol Belg*. 1997 Apr-Jun;60(2):156-62.
69. Banno N, Akihisa T, Tokuda H, et al. Triterpene acids from the leaves of *Perilla frutescens* and their anti-inflammatory and antitumor-promoting effects. *Biosci Biotechnol Biochem*. 2004 Jan;68(1):85-90.
70. Huang BP, Lin CH, Chen YC, Kao SH. Anti-inflammatory effects of *Perilla frutescens* leaf extract on lipopolysaccharide-stimulated RAW264.7 cells. *Mol Med Rep*. 2014 Aug;10(2):1077-83.
71. Osakabe N, Yasuda A, Natsume M, Yoshikawa T. Rosmarinic acid inhibits epidermal inflammatory responses: anticarcinogenic effect of *Perilla frutescens* extract in the murine two-stage skin model. *Carcinogenesis*. 2004 Apr;25(4):549-57.
72. Yang EJ, Ku SK, Lee W, et al. Barrier protective effects of rosmarinic acid on HMGB1-induced inflammatory responses in vitro and in vivo. *J Cell Physiol*. 2013 May;228(5):975-82.
73. Camilleri M, Madsen K, Spiller R, Greenwood-Van Meerveld B, Verne GN. Intestinal barrier function in health and gastrointestinal disease. *Neurogastroenterol Motil*. 2012 Jun;24(6):503-12.
74. Lillestol K, Helgeland L, Arslan Lied G, et al. Indications of 'atopic bowel' in patients with self-reported food hypersensitivity. *Aliment Pharmacol Ther*. 2010 May;31(10):1112-22.
75. Makino T, Furuta A, Fujii H, et al. Effect of oral treatment of *Perilla frutescens* and its constituents on type-I allergy in mice. *Biol Pharm Bull*. 2001 Oct;24(10):1206-9.
76. Pineton de Chambrun G, Neut C, Chau A, et al. A randomized clinical trial of *Saccharomyces cerevisiae* versus placebo in the irritable bowel syndrome. *Dig Liver Dis*. 2015 Feb;47(2):119-24.
77. Thijssen AY, Jonkers DM, Leue C, et al. Dysfunctional cognitions, anxiety and depression in irritable bowel syndrome. *J Clin Gastroenterol*. 2010 Nov-Dec;44(10):e236-41.
78. Madisch A, Hotz J. Symptomatic therapy of irritable bowel syndrome. Which drug for which symptoms? *MMW Fortschr Med*. 2001 Sep 27;143(39):28-30.
79. Cash B, Sullivan S, Barghout V. Total costs of IBS: employer and managed care perspective. *Am J Manag Care*. 2005 Apr;11(1 Suppl):S7-16.
80. Drossman DA. The functional gastrointestinal disorders and the Rome III process. *Gastroenterology*. 2006 Apr;130(5):1377-90.
81. Palsson OS, Baggish JS, Turner MJ, Whitehead WE. IBS patients show frequent fluctuations between loose/watery and hard/lumpy stools: implications for treatment. *Am J Gastroenterol*. 2012 Feb;107(2):286-95.